RecruitingPhase 4

Suprainguinal Fascia Iliaca Block With vs Without Dexmedetomidine

United States120 participantsStarted 2026-01-20

Plain-language summary

The investigators are evaluating postoperative outcomes in patients undergoing hip replacement surgery performed with either spinal or general anesthesia, who also receive a suprainguinal fascia iliaca block using either perineural ropivacaine alone or ropivacaine combined with dexmedetomidine.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients undergoing elective total hip arthroplasty * 18-80 years old * ASA 1-3 classifications Exclusion Criteria: * ASA classification of 4 or greater * Infection at the site of nerve blockade * Coagulopathy * Known allergy to study medications * Chronic opioid consumption (\>3 months) * Currently using lidocaine patches * Pre-existing neuropathy * A history of CVA * High grade atrioventricular block (cardiac conduction system impairment) * Organ dysfunction (cardiac failure, respiratory failure, end stage renal disease, hepatic dysfunction, hypoalbuminemia) * Morbid obesity (≥40 kg/m2) * Prior surgery in supra and/or infrainguinal region * Non-English-speaking participants

What they're measuring

Time of administration of first analgesic after the surgery

Timeframe: Time to first analgesic request, defined as the interval (in minutes) from block administration to the first request for rescue analgesia, assessed for up to 24 hours.

Trial details

NCT IDNCT07316166

SponsorRhode Island Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-06

Contact for this trial

Vendhan Ramanujam, M.D.

401-444-5172 vramanujam@brownhealth.org

View on ClinicalTrials.gov More Postoperative Pain Management trials